MediaPharma S.r.l.
A Company focused on the discovery and development of innovative drugs for the treatment of cancer and other diseases with unmet medical need.


An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling.

Sala G, Traini S, D’Egidio M, Vianale G, Rossi C, Piccolo E, Lattanzio R, Piantelli M, Tinari N, Natali PG, Muraro R, Iacobelli S

Oncogene 8:1275-86 (2012)


LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis.

Piccolo E, Tinari N, Semeraro D, Traini S, Fichera I, Cumashi A, La Sorda R, Spinella F, Bagnato A, Lattanzio R, D’Egidio M, Di Risio A, Stampolidis P, Piantelli M, Natoli C, Ullrich A, Iacobelli S.

J Mol Med 91:83-94 (2013)


Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody.

Sara Traini, Enza Piccolo, Nicola Tinari, Cosmo Rossi, Rossana La Sorda, Francesca Spinella, Anna Bagnato, Rossano Lattanzio, Maurizia D’Egidio, Annalisa Di Risio, Federica Tomao, Antonino Grassadonia,Mauro Piantelli, Clara Natoli and Stefano Iacobelli.

Mol Cancer Ther. 3: 916-925 (2014)


An Antibody-based Blood Test Utilizing a Panel of Biomarkers as a New Method for Improved Breast Cancer Diagnosis.

Galit Yahalom, Daria Weiss, Ilya Novikov, Therese B. Bevers, Laszlo G. Radvanyi, Mei Liu, Benjamin Piura, Stefano Iacobelli, Maria T. Sandri, Enrico Cassano, Tanir M. Allweis,Arie Bitterman, Pnina Engelman, Luis M. Vence and Marvin M. Rosenberg

Biomarkers in Cancer 5: 71-80 (2013)


LGALS3BP, lectin galactoside-binding soluble 3 binding protein promotes oncogenic cellular events impeded by antibody intervention.

Pavlos Stampolidis, Axel Ullrich, and Stefano Iacobelli

Oncogene 34:39-52 (2015)

EV20, a Novel Anti ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo.

Sala G, Rapposelli IG, Ghasemi R, Piccolo E, Traini S, Capone E, Rossi C, Pelliccia A, Di Risio A, D?Egidio M, Tinari N, Muraro R, Iacobelli S

Transl Oncol 6: 676-84 ( 2013)


Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer.

Ghasemi R, Rapposelli IG, Capone E, Rossi C, Lattanzio R, Piantelli M, Sala G. Iacobelli S.

Oncogenesis 18;3:e117 (2014).


Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer.

Lattanzio R, Ghasemi R, Brancati F, Sorda RL, Tinari N, Perracchio L, Iacobelli S, Mottolese M, Natali P, Piantelli M

Oncogenesis (2014) S3:e118. doi: 10.1038.


Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.

Momeny M, Saunus JM, Marturana F, McCart Reed AE, Black D, Sala G, Iacobelli S, Holland JD, Birchmeier W, Yu D, Da Silva L, Simpson PT, Khanna K, Chenevix-Trench G and Lakhani SR.

Oncotarget (2015);6:3932-46


ErbB-3 activation by NRG-1 sustains growth and promotes Vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 

Pramudita R Prasetyanti, Emily Capone, Daniela Barcaroli, Daniela D’Agostino, Silvia Volpe, Antonina Benfante, Sander van Hooff, Valentina Iacobelli, Cosmo Rossi, Stefano Iacobelli, Jan Paul Medema, Vincenzo De Laurenzi and Gianluca Sala

Oncotarget  6:16902-11 (2015).


Prognostic relevance of LGALS3BP in human colorectal carcinoma

Enza Piccolo, Nicola Tinari, Domenica D’Addario, Cosmo Rossi, Valentina Iacobelli, Rossana La Sorda,
Rossano Lattanzio, Maurizia D’Egidio, Annalisa Di Risio, Mauro Piantelli1, Pier Giorgio Natali and Stefano Iacobelli

J Transl Med (2015) 13:248


HER-3: hub for escape mechanisms

Emily Capone, Pramudita R Prasetyanti, and Gianluca Sala

AGING, November 2015, Vol. 7 No.11


Overexpression of PY1289‑HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants

Rossano Lattanzio, Serena Veschi, Gitana Maria Aceto, Maria Cristina Curia, Alessandro Cama, Laura De Lellis, Fabiana Fantini, Domenico Angelucci, Stefano Iacobelli, Mauro Piantelli, and Pasquale Battista

Oncol Lett 12: 453-458, 2016


Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer

Gabriele Corda, Gianluca Sala, Rossano Lattanzio, Manuela Iezzi, Michele Sallese, Giorgia Fragassi, Alessia Lamolinara, Hasan Mirza, Daniela Barcaroli, Sibylle Ermler, Elisabete Silva, Hemad Yasaei, Robert F Newbold, Paola Vagnarelli, Marcella Mottolese, Pier Giorgio Natali, Letizia Perracchio, Jelmar Quist, Anita Grigoriadis, Pierfrancesco Marra,  Andrew N Tutt, Mauro Piantelli, Stefano Iacobelli, Vincenzo De Laurenzi and Arturo Sala

J Pathol 2017; 241: 350–361


Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma
Emily Capone , Enza Piccolo , Imma Fichera , Paolo Ciufici , Daniela Barcaroli , Arturo Sala , Stefano Iacobelli Vincenzo De Laurenzi , Valentina Iacobelli , Gianluca Sala

Oncotarget. 2017; 8:60368-60377


EV20-Sap, a novel anti-HER-3 Antibody-Drug Conjugate, displays promising antitumor activity in melanoma

Emily Capone, Francesco Giansanti, Sara Ponziani, Alessia Lamolinara, Manuela Iezzi, Annamaria Cimini, Francesco Angelucci, Rossana La Sorda, Vincenzo De Laurenzi, Pier Giorgio Natali, Rodolfo Ippoliti, Gianluca Sala

Oncotarget https://doi.org/10.18632/oncotarget.20728


EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma

Emily Capone, Alessia Lamolinara, Daniela D’Agostino, Cosmo Rossi, Vincenzo De Laurenzi, Manuela Iezzi, Stefano Iacobelli and Gianluca Sala

J Control Release. 2018 Mar 14;277:48-56


Secreted Gal-3 BP is a novel promising target for noninternalizing Antibody-Drug Conjugates

Francesco Giansanti, Emily Capone, Sara Ponziani, Enza Piccolo, Roberta Gentile, Alessia Lamolinara, Antonella Di Campli, Michele Sallese, Valentina Iacobelli, Annamaria Cimini, Vincenzo De Laurenzi, Rossano Lattanzio, Mauro Piantelli, Rodolfo Ippoliti, Gianluca Sala, Stefano Iacobelli

J Control Release. 2018 Dec 13;294:176-184


HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies. 

Lucía Gandullo-Sánchez , Emily Capone , Alberto Ocaña , Stefano Iacobelli , Gianluca Sala and Atanasio Pandiella

EMBO Mol Med. 2020 Apr 24:e11498. doi


A non-internalizing antibody drug conjugate targeting Galectin 3-binding protein (LGALS3BP) as a new therapeutic approach for neuroblastoma.

Emily Capone, Alessia Lamolinara, Fabio Pastorino, Roberta Gentile, Sara Ponziani, Giulia Di Vittorio, Daniela D’Agostino, Sandra Bibbò, Cosmo Rossi, Enza Piccolo, Valentina Iacobelli, Rossano Lattanzio,Valeria Panella, Michele Sallese, Vincenzo De Laurenzi, Francesco Giansanti, Arturo Sala, Manuela Iezzi, Mirco Ponzon, Rodolfo Ippoliti, Stefano Iacobelliand Gianluca Sala(Submitted)